Telo Genomics reports positive interim data for blood test predicting multiple myeloma relapse risk

• Telo Genomics released positive interim results from a retrospective multiple myeloma study on a blood-based relapse-risk assay using genomic instability measures.
• Interim analysis covered 50 patients with two-year outcomes; “Average Distance to Nuclear Center” was the strongest relapse-status predictor.
• ROC analysis showed AUC 0.849, indicating strong discrimination between patients who relapsed versus those who remained in remission.
• Trial is expected to conclude in summer 2026, supporting plans to validate the platform against established MRD approaches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telo Genomics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607160700NEWSFILECNPR____20260716_305392_1) on July 16, 2026, and is solely responsible for the information contained therein.